ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
Renal cancer metastatic | 20.01.04.012; 16.08.02.006 | 0.000278% | | Not Available |
Skin ulcer haemorrhage | 24.07.01.078; 23.07.03.021 | 0.000533% | | Not Available |
Liver carcinoma ruptured | 16.07.02.007; 09.04.02.012 | 0.003996% | | Not Available |
Portal hypertensive gastropathy | 24.08.06.006; 09.01.06.022; 07.12.01.007 | 0.000533% | | Not Available |
Corneal bleeding | 24.07.05.012; 06.07.01.005 | 0.000533% | | Not Available |
Gastric antral vascular ectasia | 24.03.03.028; 07.15.04.003 | 0.001598% | | Not Available |
Metastases to abdominal wall | 16.22.02.011; 07.16.05.007 | 0.000139% | | Not Available |
Metastases to spleen | 16.22.02.025; 01.09.02.010 | 0.000347% | | Not Available |
Pulmonary sepsis | 22.07.01.014; 11.01.11.014 | 0.000139% | | Not Available |
Impaired self-care | 08.01.03.071; 19.01.02.014 | 0.001066% | | Not Available |
Thyroid cancer metastatic | 05.02.05.009; 16.24.03.006 | 0.000764% | | Not Available |
Protein induced by vitamin K absence or antagonist II increased | 13.09.01.027 | 0.001332% | | Not Available |
Hepatic infection | 11.01.18.008; 09.01.08.014 | 0.000533% | | |
Gastric infection | 11.01.07.008; 07.19.03.003 | 0.000533% | | Not Available |
Hepatic mass | 09.01.08.015 | 0.000533% | | Not Available |
Portal vein occlusion | 24.04.07.009; 09.01.06.024 | 0.000533% | | Not Available |
Acute myeloid leukaemia recurrent | 16.01.05.004; 01.10.05.004 | 0.000139% | | Not Available |
Sputum retention | 22.02.03.012 | 0.000533% | | Not Available |
Traumatic intracranial haemorrhage | 24.07.04.034; 17.08.05.005; 12.01.10.017 | 0.000139% | | Not Available |
Paracentesis | 13.18.01.009 | 0.000533% | | Not Available |
Perforated ulcer | 08.03.06.002 | 0.000533% | | Not Available |
Grip strength decreased | 13.15.01.041 | 0.000799% | | Not Available |
Portal venous gas | 07.01.06.033 | 0.000533% | | Not Available |
Gastrointestinal telangiectasia | 24.03.03.030; 07.15.04.006 | 0.000533% | | Not Available |
Quality of life decreased | 13.18.01.013 | - | - | Not Available |
Oncologic complication | 16.32.03.025 | 0.000139% | | Not Available |
Tumour thrombosis | 24.01.01.035; 16.32.03.034 | 0.002131% | | Not Available |
Escherichia test positive | 13.08.01.009 | 0.000533% | | Not Available |
Tumour rupture | 16.32.03.033 | 0.001042% | | Not Available |
Infected dermal cyst | 23.10.02.002; 16.26.02.002; 11.01.12.024 | 0.000533% | | Not Available |